ThromboGenics Business Update – Q1 2018
Advancing Diabetic Eye Disease Portfolio
Positive Initial Topline Data from Phase 1/ 2aClinical Study evaluating THR-317, anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)
First patient enrolled in Phase 2 study evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab,Lucentis®) in patients with DME
€10 Million equity investment from Novartis Pharma AG
Total cash & investments of €108.5 million as of March 31, 2018
- Positive initial results from a Phase 1/2 clinical study evaluating primarily safety, tolerability and biological activity of two dose levels of THR-317 (anti-PIGF) for the treatment of diabetic macular edema (DME) were announced, supporting initiation of a Phase 2 study
- First patient was enrolled inthe Phase 2 study evaluating efficacy and safety of intravitreal anti-PlGF (THR-317) administered in combination with anti-VEGF (ranibizumab, Lucentis®), for the treatment of DME
- THR-149 (plasma kallikrein inhibitor) and THR-687 (integrin antagonist) for diabetic retinopathy (DR) and/or DME are on track to enter Phase 1 clinical studies in H1 2018 and mid-2018 respectively
- Further novel diabetic eye disease drug candidates are being studied with at least one expected to enter pre-clinical development in 2018
- On 26 January 2018, the completion of an equity investment of €10 million by Novartis Pharma AG in ThromboGenics capital was confirmed
- ThromboGenics had, at the end of March 2018, €108.5 million in cash and investments. This compares with€115.7 million as of the end of December 2017. Both figures include €10 million equity investment received from Novartis, as restricted cash in our account on December 31st 2017, and freed up at completion date on January 26th2018.
Leuven, Belgium – ThromboGenics NV, today issues a business update and financial update for the three-month period ending 31 March 2018.
ThromboGenics is developing a broad pipeline of disease modifying drug candidates for the treatment of diabetic eye disease, including:
THR-317– a PIGF neutralizing monoclonal antibody being developed for the potential treatment of DME. THR-317 is in a Phase 2 study evaluating the efficacy and safety of intravitreal THR-317 administered in combination with Lucentis® (ranibizumab), for the treatment of DME.
THR-149– a plasma kallikrein inhibitor being developed to treat DME. THR-149 will be evaluated in a Phase 1 open-label, multicenter, dose escalation study evaluating its safety in the treatment of DME, expected to initiate in H1 2018.
THR-687– a small molecule integrin antagonist being developed to treat a broad range of patients with diabetic eye disease. THR-687 is expected to enter the clinic around mid-2018.
These products all have different modes of action and could allow the Company to address the key segments of the rapidly growing diabetic eye disease market.
Further drug candidates are currently being explored for the treatment of diabetic eye disease and it is expected that at least one additional pre-clinical candidate will be moved into development in 2018.
Patrik De Haes, MD, ThromboGenics CEO,said: “We have had a busy start to 2018, announcing encouraging Phase 1/2a results with THR-317 and the start of a Phase 2 evaluating THR-317 in combination with Lucentis®in patients with DME. We are also about to progress our plasma-kallikrein inhibitor (THR-149) into the clinic and are on track to start clinical development of our integrin antagonist (THR-687) around mid-2018. We look forward to progressing our diabetic eye disease candidates in the coming months, in line with our strategy of multiple shots on goal.”